Sanara MedTech Inc. (SMTI)
| Market Cap | 218.84M |
| Revenue (ttm) | 107.48M |
| Net Income (ttm) | -33.58M |
| Shares Out | 9.16M |
| EPS (ttm) | -3.89 |
| PE Ratio | n/a |
| Forward PE | 96.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,570 |
| Open | 23.33 |
| Previous Close | 23.12 |
| Day's Range | 23.08 - 24.60 |
| 52-Week Range | 16.05 - 35.95 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 34.33 (+43.76%) |
| Earnings Date | Aug 12, 2026 |
About SMTI
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-... [Read more]
Financial Performance
In 2025, Sanara MedTech's revenue was $103.12 million, an increase of 18.97% compared to the previous year's $86.67 million. Losses were -$37.56 million, 288.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SMTI stock is "Strong Buy." The 12-month stock price target is $34.33, which is an increase of 43.76% from the latest price.
News
Sanara MedTech initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $35 price target Sanara develops and commercializing products for surgical wound and soft tissue management, the analys...
Sanara MedTech management to meet with Lake Street
Meeting to be held in New York on June 9 hosted by Lake Street.
Sanara MedTech Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and advisory votes on executive compensation and its voting frequency. All proposals passed, with directors elected, auditor ratified, compensation approved, and a three-year advisory vote frequency set.
Sanara MedTech reports Q1 EPS 4c vs. (7c) last year
Last night, the company also reported Q1 revenue $27.8M vs. $23.4M last year. Seth Yon, CEO, commented, “The first quarter of 2026 is the first full quarter in which the…
Sanara MedTech Earnings Call Transcript: Q1 2026
Q1 2026 delivered 19% revenue growth and a return to GAAP net profitability, driven by strong sales of core surgical products and expanded market presence. Guidance for 2026 was reaffirmed, with continued investment in sales and R&D supporting long-term growth.
Sanara MedTech Earnings release: Q1 2026
Sanara MedTech released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Sanara MedTech Quarterly report: Q1 2026
Sanara MedTech has published its Q1 2026 quarterly earnings report on May 12, 2026.
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter
Sanara MedTech Proxy statement: Proxy filing
Sanara MedTech filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Sanara MedTech Proxy statement: Proxy filing
Sanara MedTech filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Sanara MedTech Proxy statement: Proxy filing
Sanara MedTech filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Sanara MedTech initiated with a Buy at Lake Street
Lake Street initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $32 price target The firm, which estimates Sanara generates $116M of revenue with 14% AEBITDA margins for…
Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commerciali...
Sanara MedTech, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sanara MedTech, Inc. , (“ Sanara " or the "Company") ( NASDAQ : SMTI) investors that the firm has initiated an investigati...
Sanara MedTech Earnings Call Transcript: Q4 2025
Record 2025 revenue of $103.1M (up 19% YoY) and 93% gross margin reflect strong execution and focus on surgical markets. 2026 guidance projects 13–17% revenue growth, with new Vizient contract and clinical evidence supporting further expansion.
Sanara MedTech Annual report: Q4 2025
Sanara MedTech has published its Q4 2025 annual report on March 24, 2026.
Sanara MedTech Earnings release: Q4 2025
Sanara MedTech released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Sanara MedTech Annual report: Q4 2025
Sanara MedTech has published its Q4 2025 annual report on March 24, 2026.
Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance
FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commerciali...
Sanara MedTech announces publication of study on CellerateRX Surgical Powder
Sanara MedTech (SMTI) announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX Surgical Powder in the Journal of Medical Economics. The study estima...
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the stand...
Sanara MedTech Transcript: TD Cowen 46th Annual Health Care Conference
The company has transitioned to a pure-play surgical wound care focus, achieving strong revenue growth and expanding its reach to over 4,000 facilities. With three core technologies and a robust commercial strategy, it projects continued double-digit growth, stable margins, and new product launches through 2027.
Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commerciali...
Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
FORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializ...
Sanara MedTech reports Q4 preliminary net revenue $27.2M-$27.7M
Net revenue for the fourth quarter of 2025 is expected to be in the range of $27.2 million to $27.7 million, an increase of approximately 3% to 5%, compared to…